Symbols / BVS
BVS Chart
About
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides nexus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system; and Talisman pulse generator and receiver for peripheral nerve stimulation. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 594.75M |
| Enterprise Value | 924.20M | Income | 10.17M | Sales | 563.83M |
| Book/sh | 2.48 | Cash/sh | 0.63 | Dividend Yield | — |
| Payout | 0.00% | Employees | 950 | IPO | — |
| P/E | 55.50 | Forward P/E | 11.48 | PEG | — |
| P/S | 1.05 | P/B | 3.58 | P/C | — |
| EV/EBITDA | 14.01 | EV/Sales | 1.64 | Quick Ratio | 1.07 |
| Current Ratio | 1.74 | Debt/Eq | 164.61 | LT Debt/Eq | — |
| EPS (ttm) | 0.16 | EPS next Y | 0.77 | EPS Growth | — |
| Revenue Growth | -0.20% | Earnings | 2026-03-05 | ROA | 4.14% |
| ROE | 6.38% | ROIC | — | Gross Margin | 67.76% |
| Oper. Margin | 8.12% | Profit Margin | 1.80% | Shs Outstand | 66.98M |
| Shs Float | 32.99M | Short Float | 5.95% | Short Ratio | 6.82 |
| Short Interest | — | 52W High | 11.25 | 52W Low | 5.81 |
| Beta | 0.79 | Avg Volume | 265.93K | Volume | 10.34K |
| Target Price | $14.50 | Recom | None | Prev Close | $8.72 |
| Price | $8.88 | Change | 1.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$14.50
Mean price target
2. Current target
$8.66
Latest analyst target
3. DCF / Fair value
$9.10
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$8.66
Low
$13.00
High
$15.00
Mean
$14.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-09 | init | Barrington Research | — → Outperform | $13 |
| 2025-07-07 | init | Cantor Fitzgerald | — → Overweight | $12 |
| 2025-03-17 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2024-12-17 | up | JP Morgan | Underweight → Neutral | $13 |
| 2024-11-06 | main | Canaccord Genuity | Buy → Buy | $15 |
| 2024-09-27 | main | Craig-Hallum | Buy → Buy | $17 |
| 2024-08-13 | main | Canaccord Genuity | Buy → Buy | $12 |
| 2024-08-07 | main | Craig-Hallum | Buy → Buy | $12 |
| 2024-05-08 | main | Canaccord Genuity | Buy → Buy | $8 |
| 2024-03-13 | main | Craig-Hallum | Buy → Buy | $9 |
| 2023-12-07 | up | Canaccord Genuity | Hold → Buy | $7 |
| 2023-04-03 | main | Craig-Hallum | — → Hold | $5 |
| 2022-11-30 | main | Goldman Sachs | — → Neutral | $3 |
| 2022-11-22 | down | Craig-Hallum | Buy → Hold | — |
| 2022-11-10 | main | Morgan Stanley | — → Overweight | $5 |
| 2022-11-09 | down | Canaccord Genuity | Buy → Hold | — |
| 2022-11-09 | down | JP Morgan | Overweight → Underweight | — |
| 2022-10-11 | main | Morgan Stanley | — → Overweight | $11 |
| 2022-09-07 | main | Goldman Sachs | — → Neutral | $13 |
| 2022-08-12 | main | Morgan Stanley | — → Overweight | $12 |
News
RSS: Latest BVS news- Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026 - Stock Titan ue, 24 Feb 2026 21
- Barrington Research Initiates Coverage of Bioventus (BVS) with Outperform Recommendation - Nasdaq ue, 17 Feb 2026 04
- Understanding Momentum Shifts in (BVS) - Stock Traders Daily Wed, 18 Feb 2026 06
- Institutional investors own a significant stake of 36% in Bioventus Inc. (NASDAQ:BVS) - Yahoo Finance Wed, 14 Jan 2026 08
- Bioventus (NASDAQ:BVS) Shares Gap Up - Here's What Happened - MarketBeat Mon, 09 Feb 2026 08
- Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year - simplywall.st Sat, 10 Jan 2026 08
- Those who invested in Bioventus (NASDAQ:BVS) three years ago are up 413% - Yahoo Finance ue, 10 Feb 2026 08
- Exclusive: Bioventus CEO Reveals Future Growth Plans at Major Healthcare Conference - Stock Titan hu, 07 Aug 2025 07
- Bioventus (NASDAQ:BVS) Trading 1.4% Higher - What's Next? - MarketBeat Fri, 06 Feb 2026 08
- Bioventus (BVS): $17.3M One-Time Loss Raises Questions About Quality of New Profitability - simplywall.st Wed, 05 Nov 2025 08
- Bravura Solutions Limited's (ASX:BVS) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum? - Yahoo Finance ue, 11 Nov 2025 08
- Bioventus (NASDAQ:BVS) Trading Up 1.4% - Here's What Happened - MarketBeat Fri, 06 Feb 2026 08
- What To Expect From Bioventus Inc (BVS) Q3 2025 Earnings - Yahoo Finance Mon, 03 Nov 2025 08
- Bioventus (NASDAQ:BVS) Upgraded at Barrington Research - MarketBeat ue, 10 Feb 2026 08
- Investing in Bravura Solutions (ASX:BVS) three years ago would have delivered you a 289% gain - Yahoo Finance Sun, 18 Jan 2026 08
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 4375 | — | — | CHURCH KATRINA J | Officer | — | 2026-02-13 00:00:00 | D | nan |
| 1 | 12980 | — | — | D'ADAMIO ANTHONY | General Counsel | — | 2026-02-13 00:00:00 | D | nan |
| 2 | 20153 | — | — | SINGLETON MARK LEONARD | Chief Financial Officer | — | 2026-02-13 00:00:00 | D | nan |
| 3 | 93750 | — | — | CLAYPOOLE ROBERT E. | Chief Executive Officer | — | 2026-01-09 00:00:00 | D | nan |
| 4 | 10000 | — | Sale at price 7.57 per share. | NOHRA GUY P | Director | — | 2025-12-04 00:00:00 | D | 75658.0 |
| 5 | 17701 | — | Sale at price 7.42 per share. | MCMURRY-HEATH MICHELLE | Director | — | 2025-11-07 00:00:00 | D | 131255.0 |
| 6 | 7575 | — | — | BARTHOLDSON JOHN A | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-06 00:00:00 | D | nan |
| 7 | 26493 | — | — | NOHRA GUY P | Director | — | 2025-06-02 00:00:00 | D | nan |
| 8 | 26493 | — | — | SUTTER MARTIN P | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-06-02 00:00:00 | D | nan |
| 9 | 26493 | — | — | NEELS GUIDO J | Director | — | 2025-06-02 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -4.11M | -17.59M | -31.16M | -2.32M |
| TaxRateForCalcs | 0.11 | 0.21 | 0.23 | 0.26 |
| NormalizedEBITDA | 77.24M | 60.68M | 10.97M | 54.47M |
| TotalUnusualItems | -38.02M | -83.75M | -132.58M | -8.99M |
| TotalUnusualItemsExcludingGoodwill | -38.02M | -83.75M | -132.58M | -8.99M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -33.54M | -81.80M | -89.96M | 21.24M |
| ReconciledDepreciation | 49.55M | 57.37M | 55.40M | 34.88M |
| ReconciledCostOfRevenue | 143.15M | 135.63M | 135.39M | 101.68M |
| EBITDA | 39.22M | -23.07M | -121.61M | 45.48M |
| EBIT | -10.33M | -80.44M | -177.00M | 10.60M |
| NetInterestIncome | -38.79M | -40.68M | -12.02M | -1.11M |
| InterestExpense | 38.79M | 40.68M | 12.02M | 1.11M |
| NormalizedIncome | 371.84K | -15.64M | 11.46M | 27.91M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -33.54M | -156.23M | -158.70M | 19.38M |
| TotalExpenses | 547.24M | 510.32M | 546.77M | 409.85M |
| TotalOperatingIncomeAsReported | -11.98M | -81.72M | -167.23M | 12.06M |
| DilutedAverageShares | 64.55M | 62.65M | 61.39M | 45.47M |
| BasicAverageShares | 64.55M | 62.65M | 61.39M | 45.47M |
| DilutedEPS | -0.52 | -2.49 | -2.59 | -0.15 |
| BasicEPS | -0.52 | -2.49 | -2.59 | -0.15 |
| DilutedNIAvailtoComStockholders | -33.54M | -156.23M | -158.70M | 19.38M |
| NetIncomeCommonStockholders | -33.54M | -156.23M | -158.70M | 19.38M |
| NetIncome | -33.54M | -156.23M | -158.70M | 19.38M |
| MinorityInterests | 10.29M | 39.40M | 54.69M | 9.79M |
| NetIncomeIncludingNoncontrollingInterests | -43.83M | -195.62M | -213.39M | 9.59M |
| NetIncomeDiscontinuousOperations | 0.00 | -74.43M | -68.74M | -1.87M |
| NetIncomeContinuousOperations | -43.83M | -121.20M | -144.65M | 11.45M |
| TaxProvision | -5.29M | 85.00K | -44.37M | -1.97M |
| PretaxIncome | -49.13M | -121.11M | -189.03M | 9.49M |
| OtherIncomeExpense | -36.38M | -82.46M | -142.35M | -10.45M |
| OtherNonOperatingIncomeExpenses | 1.65M | 1.29M | -9.77M | -1.46M |
| SpecialIncomeCharges | -38.02M | -83.75M | -132.58M | -8.99M |
| GainOnSaleOfPPE | -292.00K | -3.58M | 0.00 | 0.00 |
| WriteOff | 0.00 | 0.00 | 5.67M | |
| ImpairmentOfCapitalAssets | 36.36M | 78.61M | 124.70M | 0.00 |
| RestructuringAndMergernAcquisition | 1.37M | 1.56M | 7.88M | 3.32M |
| NetNonOperatingInterestIncomeExpense | -38.79M | -40.68M | -12.02M | -1.11M |
| InterestExpenseNonOperating | 38.79M | 40.68M | 12.02M | 1.11M |
| OperatingIncome | 26.04M | 2.03M | -34.66M | 21.05M |
| OperatingExpense | 362.19M | 326.17M | 365.74M | 281.65M |
| DepreciationAmortizationDepletionIncomeStatement | 7.65M | 8.84M | 9.75M | 8.36M |
| DepreciationAndAmortizationInIncomeStatement | 7.65M | 8.84M | 9.75M | 8.36M |
| ResearchAndDevelopment | 13.64M | 13.45M | 23.85M | 19.04M |
| SellingGeneralAndAdministration | 340.89M | 303.88M | 332.13M | 254.25M |
| GrossProfit | 388.23M | 328.19M | 331.08M | 302.71M |
| CostOfRevenue | 185.05M | 184.15M | 181.04M | 128.19M |
| TotalRevenue | 573.28M | 512.35M | 512.12M | 430.90M |
| OperatingRevenue | 573.28M | 512.35M | 512.12M | 430.90M |
| Line Item | 2023-12-31 | 2022-12-31 | ||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | 0.00 | ||
| OrdinarySharesNumber | 65.76M | 63.27M | 62.06M | 59.55M |
| ShareIssued | 65.76M | 63.27M | 62.06M | 59.55M |
| NetDebt | 294.05M | 357.88M | 387.88M | 313.75M |
| TotalDebt | 335.63M | 394.85M | 418.07M | 357.68M |
| TangibleBookValue | -264.25M | -316.22M | -322.07M | -383.89M |
| InvestedCapital | 483.57M | 568.44M | 743.30M | 816.61M |
| WorkingCapital | 65.21M | 92.50M | -31.44M | 82.24M |
| NetTangibleAssets | -264.25M | -316.22M | -322.07M | -383.89M |
| CommonStockEquity | 147.94M | 173.59M | 325.24M | 458.92M |
| TotalCapitalization | 456.23M | 540.59M | 710.25M | 798.57M |
| TotalEquityGrossMinorityInterest | 185.60M | 221.12M | 412.22M | 533.79M |
| MinorityInterest | 37.66M | 47.53M | 86.98M | 74.86M |
| StockholdersEquity | 147.94M | 173.59M | 325.24M | 458.92M |
| GainsLossesNotAffectingRetainedEarnings | -2.57M | 794.00K | -110.00K | 179.00K |
| OtherEquityAdjustments | -2.57M | 794.00K | -110.00K | 179.00K |
| RetainedEarnings | -355.08M | -321.54M | -165.31M | -6.60M |
| AdditionalPaidInCapital | 505.51M | 494.25M | 490.58M | 465.27M |
| CapitalStock | 82.00K | 79.00K | 78.00K | 75.00K |
| CommonStock | 82.00K | 79.00K | 78.00K | 75.00K |
| TotalLiabilitiesNetMinorityInterest | 542.35M | 589.79M | 960.43M | 692.07M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 331.95M | 414.30M | 656.41M | 511.21M |
| OtherNonCurrentLiabilities | 23.10M | 46.08M | 40.24M | 38.05M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 228.91M | ||
| NonCurrentDeferredLiabilities | 564.00K | 1.21M | 2.25M | 133.52M |
| NonCurrentDeferredTaxesLiabilities | 564.00K | 1.21M | 2.25M | 133.52M |
| LongTermDebtAndCapitalLeaseObligation | 308.29M | 367.00M | 385.01M | 339.64M |
| LongTermDebt | 308.29M | 367.00M | 385.01M | 339.64M |
| CurrentLiabilities | 210.40M | 175.50M | 304.02M | 180.86M |
| OtherCurrentLiabilities | 43.53M | 24.52M | 139.64M | 24.94M |
| CurrentDeferredLiabilities | 117.61M | 0.00 | ||
| CurrentDebtAndCapitalLeaseObligation | 27.34M | 27.85M | 33.06M | 18.04M |
| CurrentDebt | 27.34M | 27.85M | 33.06M | 18.04M |
| OtherCurrentBorrowings | 27.34M | 27.85M | 33.06M | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 7.60M | 9.71M | 11.43M | 21.54M |
| PayablesAndAccruedExpenses | 131.93M | 113.42M | 119.89M | 116.34M |
| CurrentAccruedExpenses | 104.38M | 85.64M | 80.62M | 91.29M |
| InterestPayable | 5.32M | 6.61M | 217.00K | |
| Payables | 27.56M | 27.79M | 39.27M | 25.05M |
| TotalTaxPayable | 3.87M | 4.75M | 2.57M | 8.14M |
| AccountsPayable | 23.69M | 23.04M | 36.70M | 16.91M |
| TotalAssets | 727.96M | 810.91M | 1.37B | 1.23B |
| TotalNonCurrentAssets | 452.35M | 542.91M | 1.10B | 962.76M |
| OtherNonCurrentAssets | 1.89M | 3.14M | 408.62M | 79.29M |
| NonCurrentDeferredAssets | 4.75M | 0.00 | 0.00 | 481.00K |
| NonCurrentDeferredTaxesAssets | 4.75M | 0.00 | 0.00 | 481.00K |
| InvestmentsAndAdvances | 2.64M | 29.29M | ||
| GoodwillAndOtherIntangibleAssets | 412.19M | 489.81M | 647.31M | 842.82M |
| OtherIntangibleAssets | 404.73M | 482.35M | 639.85M | 695.19M |
| Goodwill | 7.46M | 7.46M | 7.46M | 147.62M |
| NetPPE | 33.52M | 49.96M | 44.15M | 40.17M |
| AccumulatedDepreciation | -50.19M | -40.50M | -30.79M | -23.10M |
| GrossPPE | 83.70M | 90.46M | 74.94M | 63.27M |
| Leases | 4.09M | 3.76M | 3.35M | 3.13M |
| OtherProperties | 32.21M | 42.50M | 33.52M | 31.04M |
| MachineryFurnitureEquipment | 47.40M | 44.20M | 38.07M | 29.10M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 275.61M | 268.00M | 272.57M | 263.10M |
| OtherCurrentAssets | 14.16M | 16.91M | 18.55M | 15.00M |
| AssetsHeldForSaleCurrent | 0.00 | 2.78M | ||
| RestrictedCash | 23.00K | 5.28M | ||
| PrepaidAssets | 4.44M | 12.24M | ||
| Inventory | 92.47M | 91.33M | 84.77M | 61.69M |
| InventoriesAdjustmentsAllowances | -1.85M | -1.33M | ||
| FinishedGoods | 70.38M | 70.27M | 66.31M | 50.80M |
| RawMaterials | 22.10M | 21.06M | 18.45M | 12.21M |
| Receivables | 127.39M | 122.79M | 136.29M | 124.96M |
| AccountsReceivable | 127.39M | 122.79M | 136.29M | 124.96M |
| AllowanceForDoubtfulAccountsReceivable | -2.86M | -4.22M | -7.02M | -3.40M |
| GrossAccountsReceivable | 130.26M | 127.01M | 143.32M | 128.37M |
| CashCashEquivalentsAndShortTermInvestments | 41.58M | 36.96M | 30.19M | 43.93M |
| CashAndCashEquivalents | 41.58M | 36.96M | 30.19M | 43.93M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 37.79M | 7.98M | -15.02M | 2.10M |
| RepaymentOfDebt | -59.58M | -87.26M | -45.04M | -111.25M |
| IssuanceOfDebt | 0.00 | 64.00M | 104.66M | 277.45M |
| IssuanceOfCapitalStock | 2.44M | 778.00K | 5.82M | 109.41M |
| CapitalExpenditure | -1.01M | -7.36M | -1.48M | -20.89M |
| EndCashPosition | 41.58M | 36.96M | 31.84M | 99.21M |
| BeginningCashPosition | 36.96M | 31.84M | 99.21M | 86.84M |
| EffectOfExchangeRateChanges | -2.56M | 629.00K | 521.00K | -228.00K |
| ChangesInCash | 7.18M | 4.50M | -67.90M | 12.60M |
| FinancingCashFlow | -54.58M | -26.65M | 62.08M | 273.37M |
| CashFlowFromContinuingFinancingActivities | -54.58M | -26.65M | 62.08M | 273.37M |
| NetOtherFinancingCharges | 2.56M | -4.17M | -3.37M | -2.24M |
| CashDividendsPaid | 0.00 | -367.00K | ||
| CommonStockDividendPaid | 0.00 | -367.00K | ||
| NetCommonStockIssuance | 2.44M | 778.00K | 5.82M | 109.41M |
| CommonStockIssuance | 2.44M | 778.00K | 5.82M | 109.41M |
| NetIssuancePaymentsOfDebt | -59.58M | -23.26M | 59.62M | 166.20M |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | -20.00M | |||
| ShortTermDebtIssuance | 20.00M | |||
| NetLongTermDebtIssuance | -59.58M | -23.26M | 59.62M | 166.20M |
| LongTermDebtPayments | -59.58M | -87.26M | -45.04M | -111.25M |
| LongTermDebtIssuance | 0.00 | 64.00M | 104.66M | 277.45M |
| InvestingCashFlow | 22.96M | 15.81M | -116.44M | -283.76M |
| CashFromDiscontinuedInvestingActivities | 0.00 | -11.51M | -104.84M | 0.00 |
| CashFlowFromContinuingInvestingActivities | 22.96M | 27.31M | -11.60M | -283.76M |
| NetOtherInvestingChanges | -75.00K | |||
| NetInvestmentPurchaseAndSale | -709.00K | 0.00 | -10.04M | |
| NetBusinessPurchaseAndSale | 24.68M | 34.67M | 0.00 | -262.87M |
| SaleOfBusiness | 24.68M | 34.67M | 0.00 | 0.00 |
| PurchaseOfBusiness | 0.00 | -104.84M | -262.87M | |
| NetIntangiblesPurchaseAndSale | 0.00 | -1.48M | -7.37M | |
| PurchaseOfIntangibles | 0.00 | -1.48M | -7.37M | |
| NetPPEPurchaseAndSale | -1.01M | -7.36M | -1.48M | -13.52M |
| PurchaseOfPPE | -1.01M | -7.36M | -1.48M | -13.52M |
| OperatingCashFlow | 38.80M | 15.34M | -13.54M | 22.99M |
| CashFromDiscontinuedOperatingActivities | 0.00 | -2.17M | -2.13M | 0.00 |
| CashFlowFromContinuingOperatingActivities | 38.80M | 17.51M | -11.41M | 22.99M |
| ChangeInWorkingCapital | -11.78M | -3.18M | -29.73M | -15.14M |
| ChangeInOtherWorkingCapital | -2.52M | -1.97M | 9.66M | -16.49M |
| ChangeInPayablesAndAccruedExpense | 17.85M | -5.28M | -3.10M | 18.21M |
| ChangeInInventory | -16.43M | -5.99M | -18.62M | 3.18M |
| ChangeInReceivables | -10.67M | 10.05M | -17.67M | -20.05M |
| ChangesInAccountReceivables | -10.67M | 10.05M | -17.67M | -20.05M |
| OtherNonCashItems | 4.23M | 2.43M | 1.49M | -1.36M |
| StockBasedCompensation | 10.06M | 2.72M | 17.59M | 19.84M |
| ProvisionandWriteOffofAssets | -434.00K | -1.10M | 5.19M | 485.00K |
| AssetImpairmentCharge | 36.36M | 78.61M | 134.98M | 7.04M |
| DeferredTax | -5.39M | -2.38M | -46.66M | -9.76M |
| DeferredIncomeTax | -5.39M | -2.38M | -46.66M | -9.76M |
| DepreciationAmortizationDepletion | 49.55M | 57.37M | 55.40M | 34.88M |
| DepreciationAndAmortization | 49.55M | 57.37M | 55.40M | 34.88M |
| OperatingGainsLosses | 33.00K | 4.24M | -5.01M | -24.45M |
| PensionAndEmployeeBenefitExpense | 0.00 | 0.00 | -24.36M | |
| GainLossOnInvestmentSecurities | -6.40M | -2.73M | ||
| NetForeignCurrencyExchangeGainLoss | -259.00K | 665.00K | 1.38M | 472.00K |
| NetIncomeFromContinuingOperations | -43.83M | -121.20M | -144.65M | 11.45M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BVS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|